Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteInterferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.Using antibodies to target cancer therapeutics.Designing immunoconjugates for cancer therapy.Current treatment landscape for relapsed and/or refractory multiple myeloma.A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.
P2860
Q28066935-22A96785-B341-4CB3-8B6D-53398A6A9259Q34734013-B47AA324-A3E1-457B-97D6-E6494ABEF100Q35163167-92A70B0F-698C-48BA-85BE-5D45321FE102Q36127898-F3687DD6-C4C8-4429-BE57-050FA6D57BDDQ37698921-51DA4D5E-B10C-4B3B-9779-BE1455FD0D5AQ38014920-66BA57B3-E744-4AE8-8690-E74AA6BA68ECQ38017203-01DD7D12-8DE8-4456-8E81-5557FFE0B344Q38271032-C26050F0-9AA0-432D-8487-9030DA589CD7Q38899715-A8DBE7F7-9BED-4A65-B4CF-0F72A4402E75Q44645655-2672CDFF-60B6-4D1F-86C4-3B75F4433C25Q44797709-9FC46960-F203-48F4-A86E-624DE1EB1727Q44882002-DF84185F-F040-46B1-8C14-3D40CE66E532
P2860
Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Preclinical studies on targete ...... n diverse hematologic cancers.
@ast
Preclinical studies on targete ...... n diverse hematologic cancers.
@en
type
label
Preclinical studies on targete ...... n diverse hematologic cancers.
@ast
Preclinical studies on targete ...... n diverse hematologic cancers.
@en
prefLabel
Preclinical studies on targete ...... n diverse hematologic cancers.
@ast
Preclinical studies on targete ...... n diverse hematologic cancers.
@en
P2093
P2860
P1433
P1476
Preclinical studies on targete ...... n diverse hematologic cancers.
@en
P2093
Chien-Hsing Chang
David M Goldenberg
Diane L Rossi
Edmund A Rossi
Rhona Stein
Thomas M Cardillo
P2860
P304
P356
10.1182/BLOOD-2011-03-343145
P407
P577
2011-06-16T00:00:00Z